Possibilities of improving the efficacy and safety of etiopathogenetic therapy of acute sinusitis

Introduction. Acute inflammatory diseases of the paranasal sinuses (PNS) have a high frequency, risks of transition to chronic forms and occurrence of various complications.

Aim. To increase the effectiveness of complex therapy of acute sinusitis by influencing the etiopathogenetic mechanisms of the disease with a herbal medicinal product Sinupret extract.

Materials and methods. 72 patients aged 19 to 54 years participated in the study, including males (n = 42) and females (n = 30), with a diagnosis of acute sinusitis (J01). The patients were randomly divided into two groups. Patients of the 1st main group (n = 37), in addition to the standard treatment, received a herbal medicinal product with pronounced anti-inflammatory and secretolytic effects for 7 days, and persons of the 2nd control group (n = 35) received treatment according to the latest clinical recommendations. According to the SF-36 questionnaire, the coefficient of poor quality of life of patients was determined. The clinical condition of the patients was assessed on the on the 3rd, 5th and 7th day after the start of treatment.

Results and discussion. A decrease in the severity of subjective and objective symptoms of acute sinusitis during treatment was observed in both groups, but in patients of the main group who additionally took a multicomponent phytoniringovy drug, they were achieved faster, starting from 3rd day of therapy. By the end of treatment (7th day), nasal breathing improved significantly and amounted to 95.8% in the 1st group patients, while in the 2nd group patients this indicator was only 67%. Similar indicators were noted earlier for postnasal congestion, dysosmia, cephalgia, rhinorrhea, and restoration of mucociliary clearance.

Conclusions. The use of a multicomponent phytonoring drug in the complex therapy of acute sinusitis at an earlier stage reduces the severity of clinical symptoms and inflammatory manifestations, is well tolerated by patients, and accelerates recovery time.

1. Пальчун ВТ (ред.). Оториноларингология. Национальное руководство. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2022. 1024 с. Режим доступа: https://www.rosmedlib.ru/book/ISBN9785970466698.html.

2. Krivopalov AA, Ryazantsev SV, Shatalov VA, Shervashidze SV. Acute rhinitis: new therapeutic possibilities. Meditsinskiy Sovet. 2017;(8):18–23. (In Russ.) https://doi.org/10.21518/2079-701X-2017-8-18-23.

3. Карнеева ОВ, Юнусов АС, Гуров АВ, Абдулкеримов ХТ, Рязанцев СВ, Карпова ЕП и др. Острый синусит: клинические рекомендации. М.; 2024. 49 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/313_3.

4. Krivopalov AA. Rhinosinusitis: classification, epidemiology, etiology and treatment. Meditsinskiy Sovet. 2016;(6):22–25. (In Russ.) https://doi.org/10.21518/2079-701X-2016-6-22-25.

5. Чуланов ВП, Горелов АВ, Малявин АГ, Зайцев АА, Малеев ВВ, Арсланова ЛВ и др. Острые респираторные вирусные инфекции (ОРВИ) у взрослых: клинические рекомендации. М.; 2021. 70 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/724_1.

6. Gurov AV, Yushkina MA, Muzhichkova AV. Postviral rhinosinusitis, focus on pathogenetic therapy. Vestnik Oto-Rino-Laringologii. 2023;88(3):38–43. (In Russ.) https://doi.org/10.17116/otorino20228803138.

7. Garashchenko TI, Tarasova GD, Yunusov AS, Tulina AS, Garashchenko MV. Post-viral rhinosinusitis in children: the possibilities of topical monotherapy. Rossiiskaya Otorinolaringologiya. 2020;19(1):110–117. (In Russ.) https://doi.org/10.18692/1810-4800-2020-1-110-117.

8. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72–e112. https://doi.org/10.1093/cid/cir1043.

9. Sharma GK, Lofgren DH, Hohman MH, Taliaferro HG. Recurrent Acute Rhinosinusitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459372/.

10. Weldon D. Diagnosis and management of rhinitis. Prim Care. 1998;25(4):831–848. https://doi.org/10.1016/s0095-4543(05)70091-9.

11. Buensalido JAL, Valencia JCB. Rhinovirus (RV) Infection (Common Cold). Medscape. 2019;25. Available at: https://emedicine.medscape.com/article/227820-overview.

12. Korkmazov MYu, Kornova NV, Lengina MA, Smirnov AA, Korkmazov AM, Dubinets ID. Effective antibiotic therapy for community-acquired otorhinolaryngological respiratory infection (clinical description). Meditsinskiy Sovet. 2022;16(20):73–81. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-20-73-81.

13. Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis and management. Med Mycol. 2009;47(Suppl. 1):S324–S330. https://doi.org/10.1080/13693780802314809.

14. Aring AM, Chan MM. Current Concepts in Adult Acute Rhinosinusitis. Am Fam Physician. 2016;94(2):97–105. Available at: https://www.aafp.org/pubs/afp/issues/2016/0715/p97.html.

15. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl.):S1–S39. https://doi.org/10.1177/0194599815572097.

16. Podkopaeva JJ, Krivopalov AA. Сurrent understanding of the diagnosis and treatment of chronic bilateral laryngeal paralytic stenosis. Rossiiskaya Otorinolaringologiya. 2013;(6):146–155. (In Russ.) Available at: https://med-click.ru/uploads/files/docs/sovremennye-predstavleniya-o-diagnostike-i-lechenii-hronicheskih-dvustoronnih-paraliticheskih-stenozov-gortani-literaturnyy-obzor.pdf.

17. Karpishchenko SA, Krivopalov AA, Eremin SA, Shapkina PA, Chufistova AV. Topical antimicrobial therapy of infectious and inflammatory diseases of the nose and paranasal sinuses. RMJ. 2020;28(5):26–30. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Topicheskaya_antimikrobnaya_terapiya_infekcionno-vospalitelynyh_zabolevaniy_nosa_i_okolonosovyh_pazuh/.

18. Ianov IuK, Krivopalov AA, Korneyenkov AA, Shcherbuk YuA, Artyushkin SA, Vakhrushev SG. The modern epidemiological characteristics of oto- and rhinosinusogenic intracranial complications. Vestnik Oto-Rino-Laringologii. 2015;80(6):32–37. (In Russ.) https://doi.org/10.17116/otorino201580632-37.

19. Krivopalov AA, Riazantsev SV, Eremin SA, Zakharova GP, Shabalin VV, Shamkina PA, Chernushevich II. The question about the topical antibiotic therapy of acute rhinosinusitis. Russian Vestnik Oto-Rino-Laringologii. 2019;84(2):50–56. (In Russ.) https://doi.org/10.17116/otorino20198402150.

20. Krivopalov AA, Yanov YuK, Shatalov VA, Rubin AN, Shcherbuk AYu, Artyushkin SA et al. Clinicodiagnostic features of otorhinosinusogenic intracranial pyoinflammatory diseases complicated by sepsis. Grekov’s Bulletin of Surgery. 2016;175(6):13–19. (In Russ.) https://doi.org/10.24884/0042-4625-2016-175-6-13-19.

21. Wyler B, Mallon WK. Sinusitis Update. Emerg Med Clin North Am. 2019;37(1):41–54. https://doi.org/10.1016/j.emc.2018.09.007.

22. Lee S, Woodbury K, Ferguson BJ. Use of nasopharyngeal culture to determine appropriateness of antibiotic therapy in acute bacterial rhinosinusitis. Int Forum Allergy Rhinol. 2013;3(4):272–275. https://doi.org/10.1002/alr.21102.

23. Korkmazov MYu. Bioresonance. Main principles of bioresonance and electromagnetic therapy. Vestnik Oto-Rino-Laringologii. 2008;(2):59–61. (In Russ.) Available at: https://elibrary.ru/isdvvd.

24. Huang SW, Small PA Jr. Rapid diagnosis of bacterial sinusitis in patients using a simple test of nasal secretions. Allergy Asthma Proc. 2008;29(6):640–643. https://doi.org/10.2500/aap.2008.29.3163.

25. Ebell MH, McKay B, Dale A, Guilbault R, Ermias Y. Accuracy of Signs and Symptoms for the Diagnosis of Acute Rhinosinusitis and Acute Bacterial Rhinosinusitis. Ann Fam Med. 2019;17(2):164–172. https://doi.org/10.1370/afm.2354.

26. Korkmazov MYu, Yastremsky AP, Kornova NV, Lengina MA, Korkmazov AM. Therapeutic and diagnostic approaches in the treatment of chronic tonsillitis. Meditsinskiy Sovet. 2022;16(20):90–99. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-20-90-99.

27. DeMuri G, Wald ER. Acute bacterial sinusitis in children. Pediatr Rev. 2013;34(10):429–437;quiz 437. https://doi.org/10.1542/pir.34-10-429.

28. Korkmazov MYu, Kazachkov EL, Lengina MA, Dubinets ID, Korkmazov AM. Cause-effect factors of rhinosinusitis poliposa development. Russian Rhinology. 2023;31(2):124–130. (In Russ.) https://doi.org/10.17116/rosrino202331021124.

29. Berger G, Kattan A, Bernheim J, Ophir D, Finkelstein Y. Acute sinusitis: a histopathological and immunohistochemical study. Laryngoscope. 2000;110(12):2089–2094. https://doi.org/10.1097/00005537-200012000-00022.

30. Rosenfeld RM. Clinical practice. Acute Sinusitis in Adults. N Engl J Med. 2016;375(10):962–970. https://doi.org/10.1056/NEJMcp1601749.

31. Korkmazov MY, Lengina MA, Korkmasova M, Kravchenko AYu. Effect of post-COVID syndrome on the quality of life of patients with allergic rhinitis and eosinophilic phenotype of chronic polyposis rhinosinusitis. Medical Journal of the Russian Federation. 2023;29(4):277–290. (In Russ.) https://doi.org/10.17816/medjrf472079.

32. Thomas M, Bomar PA. Upper respiratory tract infection. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532961/.

33. Krett JD, Beckham JD, Tyler KL, Piquet AL, Chauhan L, Wallace CJ et al. Neurology of Acute Viral Infections. Neurohospitalist. 2022;12(4):632–646. https://doi.org/10.1177/19418744221104778.

34. Korkmazov MYu, Angelovich MS, Lengina MA, Belousov SYu. Clinical case of angiosarcoma of ethmoidal labyrinth and frontal sinus, issues of morphological verification of diagnosis. Russian Bulletin of Otorhinolaryngology. 2022;87(4):102–106. (In Russ.) https://doi.org/10.17116/otorino202287041102.

35. Cao ZZ, Xiang HJ, Gao JJ, Huang SY, Zheng B, Zhan X et al. Prevalence of allergy in children with acute rhinosinusitis. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018;32(18):1377–1382. (In Chinese) https://doi.org/10.13201/j.issn.1001-1781.2018.18.004.

36. Shaikh N, Wald ER, Jeong JH, Kurs-Lasky M, Nash D, Pichichero ME et al. Development and Modification of an Outcome Measure to Follow Symptoms of Children with Sinusitis. J Pediatr. 2019;207:103–108.e1. https://doi.org/10.1016/j.jpeds.2018.11.016.

37. Khisamova AA, Gizinger OA, Kornova NV, Zyryanova KS, Korkmazov AM, Beloshangin AS. Studies of immunological and microbiological efficiency of the therapy of curcumin and methionine in the developed capsules. Russian Journal of Immunology. 2021;24(2):305–310. (In Russ.) https://doi.org/10.46235/1028-7221-1001-SOI.

38. Svistushkin VM, Toporkova LA. Modern possibilities of acute rhinosinusites phytotherapy. Meditsinskiy Sovet. 2016;(18):38–41. (In Russ.) https://doi.org/10.21518/2079-701X-2016-18-38-41.

39. Abdulkerimov Kh T, Kartashova KI, Abdulkerimov ZKh, Egorushkina AV, Shamanskaya KV, Davydov RS et al. Comparative evaluation of the effectiveness of the drug Sinupret in preoperative preparation and the postoperative period of observation (treatment) during planned rhino-surgical interventions. Vestnik Oto-Rino-Laringologii. 2023;88(4):103–109. (In Russ.) https://doi.org/10.17116/otorino202288041103.

40. Jund R, Mondigler M, Stammer H, Stierna P, Bachert C. Herbal medicinal product Sinupret extract (BNO 1016) is safe and effective in the treatment of acute viral rhinosinusitis. Consilium Medicum. 2022;24(3):186–192. (In Russ.) https://doi.org/10.26442/20751753.2022.3.201314.

41. Puchelle G, Aug F, Pham OT, Bertrand A. Comparison of three methods for measuring nasal mucocilliary clearance in man. Acta Otolaryngol. 1981;91(3-4):297–303. https://doi.org/10.3109/00016488109138511.